Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
05/10/26	SEK 0.3825	-4.38%	4,412,613
02/10/26	SEK 0.4000	-1.72%	4,891,049
01/10/26	SEK 0.4070	-2.86%	2,498,977
30/09/26	SEK 0.4190	+1.21%	5,271,461
29/09/26	SEK 0.4140	-0.60%	1,013,001

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 03:00:00 06/10/26 am AEDT			5-day change	1st Jan Change
0.3825 ^SEK	-4.38%		-8.93%	-53.86%

02/10	Alzinova Broadens Shareholder Base With New Investor	RE
02/10	Alzinova's main shareholder sells shares for SEK6.5m, subscribes to its pro rata portion of the offering	FW

Market Cap	77.51M 7.73M 6.89M 6.42M 5.84M 11.02M 744M 11.09M 30.16M 380M 29.01M 28.38M 1.23B	P/E 2026 *	-1.47x	P/E 2027 *	-1.03x
Enterprise Value	61.51M 6.13M 5.46M 5.1M 4.64M 8.75M 590M 8.8M 23.94M 301M 23.02M 22.52M 976M	EV / Sales 2026 *	1.96x	EV / Sales 2027 *	-
Free-Float	46.92%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

02/10	Alzinova Broadens Shareholder Base With New Investor	RE
02/10	Alzinova's main shareholder sells shares for SEK6.5m, subscribes to its pro rata portion of the offering	FW
30/09	Alzinova completes Alzheimer's study with Amsterdam UMC	FW
25/09	Alzinova's Phase II Study to Be Presented at Alzheimer's Conference	FW
22/09	Alzinova Initiates Global Phase Ii Start-Up of Therapeutic Vaccine Alz-101 and Advances Blood-Based Diagnostic Program	CI
12/09	Stockholm stocks ended Friday higher	FW
11/09	Calendar Monday September 14 - Friday September 18	FW
11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
11/09	Asker plunges on double downgrade, OMXS30 index up 0.3 percent	FW
11/09	Asker plunges on choppy Stockholm market	FW
11/09	Stockholm's stock exchange is expected to open Friday on a mixed note	FW
11/09	Alzinova Resolves On Rights Issue Of SEK 51 Mln	RE
11/09	Alzinova Starts Preparations for Mid-stage Trial of Alzheimer's Disease Vaccine Candidate	MT

Alzinova AB Stock

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

11/09	Alzinova: Redeye cuts justified value to SEK 0.90	FW
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
08/04	RX Securities sees potential upside for Alzinova from Alzheimer's diagnostic collaboration	FW
26/03	DNB Carnegie sees reduced financing risk for Alzinova, but partnership remains critical	FW

02/10	Alzinova broadens its shareholder base with a new institutional investor, while its principal shareholder subscribes for its full pro rata share in the ongoing rights issue	AQ
01/10	Alzinova : The last day of trading in unit rights in Alzinova's rights issue	PU
01/10	The last day of trading in unit rights in Alzinova’s rights issue	AQ
01/10	Alzinova: Supportive early results for diagnostics programme	AQ
30/09	Alzinova : completes study with Amsterdam UMC - results support continued development and partnership discussions in blood-based Alzheimer's diagnostics	PU

1 day	-4.38%
1 week	-8.93%
Current month	-8.71%
1 month	-53.52%
3 months	-22.73%
6 months	-36.25%
Current year	-53.86%

1 week	0.37	0.45
1 month	0.37	1.04
Current year	0.37	1.61
1 year	0.37	2.28
3 years	0.37	4.62
5 years	0.37	7.98
10 years	0.37	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-4.38%	-8.93%	-65.04%	-86.58%	8.08M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-0.37%	-3.88%	+19.75%	+78.35%	57.39B
LONZA GROUP AG	+1.63%	+0.98%	+3.83%	+38.21%	47.64B
REVOLUTION MEDICINES, INC.	+0.50%	+1.32%	+344.62%	+753.25%	44.29B
IQVIA HOLDINGS INC.	+3.05%	-1.58%	+28.78%	+35.46%	42.5B
BEONE MEDICINES AG	+1.00%	+0.22%	+5.17%	+113.80%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+4.53%	+31.34%	+26.92%	28.53B
BIONTECH SE	+0.76%	-0.89%	-7.44%	-11.43%	24.34B
Average	+0.74%	-1.01%	+41.97%	+109.62%	39.05B
Weighted average by Cap.	+1.55%	-0.84%	+58.06%	+140.74%

	2026 *	2027 *
Net sales	31.35M 3.13M 2.79M 2.6M 2.36M 4.46M 301M 4.49M 12.2M 154M 11.73M 11.48M 497M	-
Net income	32.1M 3.2M 2.85M 2.66M 2.42M 4.57M 308M 4.59M 12.49M 157M 12.01M 11.75M 509M	-77M -7.68M -6.84M -6.38M -5.81M -10.95M -739M -11.02M -29.97M -377M -28.81M -28.19M -1.22B
Net Debt	-16M -1.6M -1.42M -1.33M -1.21M -2.28M -154M -2.29M -6.23M -78.42M -5.99M -5.86M -254M	-19M -1.89M -1.69M -1.57M -1.43M -2.7M -182M -2.72M -7.39M -93.12M -7.11M -6.96M -301M